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Abstract
African American (AA) men have a higher incidence and significantly higher mortality rates from prostate cancer
than white men, but the biological basis for these differences are poorly understood. Few studies have been carried
out to determine whether there are areas of allelic loss or gain in prostate cancers from AA men that are over-
represented in or specific to this group. To better understand the molecular mechanisms of prostate cancer in
AA men, we have analyzed 20 prostate cancers from AA men with high-density single-nucleotide polymorphism
arrays to detect genomic copy number alterations. We identified 17 regions showing significant loss and 4 regions
with significant gains. Most of these regions had been linked to prostate cancer by previous studies of copy number
alterations of predominantly white patients. We identified a novel region of loss at 4p16.3, which has been shown to
be lost in breast, colon, and bladder cancers. Comparison of our primary tumors with tumors from white patients
from a previously published cohort with similar pathological characteristics showed higher frequency of loss of at
numerous loci including 6q13-22, 8p21, 13q13-14, and 16q11-24 and gains of 7p21 and 8q24, all of which had higher
frequencies in metastatic lesions in this previously published cohort. Thus, the clinically localized cancers from AA
men more closely resembled metastatic cancers from white men. This difference may in part explain the more ag-
gressive clinical behavior of prostate cancer in AA men.
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Introduction
Prostate cancer is the most common visceral malignancy in American
men and the third leading cause of cancer deaths. It is well estab-
lished that African American (AA) men have both a higher incidence
and significantly higher mortality rates from prostate cancer than white
men. Indeed, AA men have the highest incidence of prostate cancer in
the world and are twice as likely to die of prostate cancer as white
Americans. The reason for this difference in incidence and mortality
is unclear (for a recent review, see Freedland and Isaacs [1]). Whereas
some of the difference in mortality can be attributed to socioeconomic
factors, a number of studies have shown that there is a still a higher
mortality rate from prostate cancer in AA men even after adjustment
for socioeconomic factors [2,3]. Thus, as concluded by Freedland and
Isaacs [1], it is likely that in addition to socioeconomic and cultural
factors, biological differences account for some of the disparity in inci-
dence and mortality for prostate cancer in AA men in comparison to
white men.
High-density mapping of genetic losses and gains can reveal po-
tential tumor suppressor or oncogene loci and might be useful for
Abbreviations: AA, African American; CGH, comparative genomic hybridization;
SNP, single-nucleotide polymorphism
Address all correspondence to: Michael Ittmann, MD, PhD, Department of Pathology,
Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.
E-mail: mittmann@bcm.tmc.edu
1This work was supported by grants from the P30 Cancer Center support grant (P30
CA125123) and the Baylor Prostate Cancer SPORE (P50CA058204; M.I.) the Dept
of Veterans Affairs Merit Review program (M.I.), an ASCO Career Development
Award (M.M.), and by the use of the facilities of the Michael E. DeBakey Veterans
Affairs Medical Center.
2These authors contributed equally to this work.
3Current address: Department of Medical Genetics, Yeditepe Medical School, Istan-
bul, Turkey.
Received 4 December 2008; Revised 11 January 2009; Accepted 12 January 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.81530
www.neoplasia.com
Volume 11 Number 3 March 2009 pp. 305–312 305
clinical classification of individual tumors. Therefore, high-throughput
methods such as comparative genomic hybridization (CGH) arrays
and single-nucleotide polymorphism (SNP) arrays have been intro-
duced for genome-wide screening for copy number alterations (CNAs)
in prostate cancer. A large number of prostate cancers have been ana-
lyzed using CGH, and these studies have identified a number of con-
sistent areas of chromosomal loss and gain [4–7]. A combined analysis
of multiple CGH studies encompassing a total of 872 cancers by Sun
et al. [4] have highlighted loss of 2q21-22, 5q13-21, 6q14-21, 8p21-23,
10q23-25, 13q14-22, 16q13-24, and 18q12-23 as well as gain of
3q23-33, 7q21-33, 8q12-23, 17q24-25, and Xq11-23 in 10% or more
of prostate cancers analyzed. SNPs may occur at more than 2 million
sites in the genome, making it possible to place SNPs at high density
along the genome for high-resolution whole genome allelotyping with
accurate copy number measurements. Several studies of allelic gain and
loss in prostate cancer using SNP arrays have been reported using SNP
arrays with 50 to 500K SNPs per array, which have shown multiple
areas of gain and loss, that are broadly similar to many of the common
areas detected with array CGH, although unique areas were also iden-
tified in these studies as well, perhaps reflecting the higher resolution of
later generation SNP arrays [8–11]. To better understand the molecular
mechanisms of prostate cancer in AA men, it will be necessary to better
define patterns of allelic gain and loss and ultimately identify the genes
underlying these chromosomal abnormalities.
Very few studies have been carried out to determine whether there
are areas of allelic loss or gain in prostate cancers from AA men that
are overrepresented in or specific to this group. Cher et al. [12] com-
pared primary prostate cancers from 16 AA and 16 white Americans
using cytogenetic CGH. They did not observe any significant differ-
ences in overall loss or gain of chromosomal regions between these two
groups, although they did observe increased rates of loss at 12q21,
15q21, and 17p12-13 in AA men. However, there are limitations to
this study. Cytogenetic CGH, as opposed to current techniques such
as array CGH or SNP arrays, has a relatively low resolution for detect-
ing losses. Cytogenetic CGH has a resolution of approximately 10Mbp
unless high-level amplification is present [13]. In contrast, the current
SNP and array CGH techniques have a resolution of less than 0.1Mbp.
We therefore carried out a study of allelic loss and gain in 20 prostate
cancers from AA men using Affymetrix 500K SNP arrays to define re-
gions of recurrent copy number gain and loss in clinically localized
prostate cancers.
Materials and Methods
Tissue Specimens and DNA Extraction
DNA were extracted from freshly frozen prostate cancer tissues
and matched benign tissue from radical prostatectomy specimens as
described previously [14]. Cancer tissues contained at least 70% cancer
and benign tissues were free of cancer or high-grade prostatic intra-
epithelial neoplasia as confirmed by frozen section before DNA extrac-
tion. All tissues were from self-identified AA men. The pathological
characteristics of these cases are summarized in Table 1. This study
was performed with institutional review board approval.
SNP Array Profiling
Affymetrix Human Mapping 500K Array Sets (Affymetrix, Santa
Clara, CA), which consisted of two chips (Nsp and Sty) with ∼250K
SNPs each, were used for genotyping each patient, according to
Affymetrix protocols. Approximately 250 ng of genomic DNA was
digested with restriction enzyme NspI or StyI and then ligated to
adaptors and polymerase chain reaction–amplified for each enzyme-
digested sample. Fragment polymerase chain reaction products were
then labeled, denatured, and hybridized to the arrays. Arrays were
washed, stained, and scanned with the upgraded Affymetrix GeneChip
Scanner 3000. Cell intensity (CEL) and data (DAT) files were generated
using the Gene Chip Operation System (GCOS) version 1.4 software.
Data Analysis
Profiles were generated on two Affymetrix array chips: Nsp and Sty,
each with ∼250K SNPs represented. In all, 20 tumors and 20 paired
normal samples were profiled, 40 profiles in all. Affymetrix CEL and
TXT files were processed using dChip [15] (with “Invariant Set” nor-
malization and “Average” modeling). In addition, total intensity scale
normalization was carried out for each patient, dividing the sum of
intensities for the normal sample profile by the sum of intensities
for the tumor sample profile, and multiplying each of the tumor values
by the resulting scaling factor. To define top genomic regions of gain or
loss by average copy number change, the average log ratio of each SNP
was computed across the tumors; cytobands with an overrepresenta-
tion of SNPs with high averages (>0.2) were called as gain, and cyto-
bands with overrepresentation of SNPs with low average (<−0.2) were
called as loss (enrichment assessed by χ 2). Copy number alterations
were visualized as color maps using the Cluster [16] and Java TreeView
[17] software.
For the genome-wide heat map and frequency plot analyses, the
500K SNP probe sets were first collapsed into the 818 cytoband loci
represented by those genes. By integrating information across neigh-
boring genes, binning provides a useful balance between minimizing
noise and maximizing mapping resolution [7,18]. For each profile,
the tumor: normal log ratios were averaged by cytoband, and each pro-
file was then centered cytoband-wise by the average of the cytoband
averages. For defining gain or loss events within each cytoband for the
purposes of the frequency plot analysis, the SD of the tumor profile
with the smallest SD across cytobands (patient 58, which showed little
widespread gain or loss; Figure 1) was used as the reference. Cytobands
with average values greater than +3SD were called as gain, and cyto-
band values less than −3 SD were called as loss. For the frequency plot
analysis, the Lapointe CGH data set was treated in the same way as the
SNP array data set (using PT187 as the reference profile, cytoband
boundaries being defined by Ensembl v50).
Table 1. Pathological Characteristics of Prostate Cancers.
Baylor Stanford
Gleason score
5 and 6 9 (45) 17 (38)
7 8 (40) 17 (38)
8 and 9 3 (15) 11 (24)
Pathological stage
T2 9 (45) 21 (47)
T3a 8 (40) 19 (42)
T3b 3 (15) 5 (11)
Number and percentage of all cases (in parentheses) are shown. Baylor cases are the 20 cases from
AA men analyzed in this study. Stanford cases are primary cancers from white men analyzed by
Lapointe et al. [7].
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Results
To investigate DNA CNAs in prostate cancer from a cohort of
AAs, we profiled 20 tumors (each with paired normal) for 500K
SNPs. A heat map representation of the entire data set (SNPs aver-
aged by cytoband) revealed widespread CNA in most tumor speci-
mens (Figure 1A) as well as extensive heterogeneity between tumors.
Numerous genes relevant to prostate cancer biology were located in
recurrent regions of copy number gain (including ETV1 at 7p21.2,
and MYC at 8q24.21) and copy number loss (including PTEN at
10q23.31, RB1 at 13q14.2, TP53 at 17p13.1, and TMPRSS2 at
21q22.3). The regions of loss and gain are broadly similar to those
reported previously for CGH studies of clinically localized prostate
cancer [4–12]. Tumor profiles in the heat map were ordered (left to
right) by their SD across cytobands, which was one measure of the
amount of CNA in each tumor. When the Gleason grade and patho-
logical stage of each patient were viewed alongside the corresponding
genome copy profiles, a trend was evident where tumors having more
genomic alterations tended to have higher grade and stage. On average,
higher-grade tumors (Gleason 7-9) had more CNA events compared
with lower-grade tumors (Gleason 5-6) with statistical significance (P <
.01; Figure 1B). A similar association of increased CNAs in more poorly
differentiated cancers has been noted by others [10,11]. It is of interest
to note that approximately 20% of the cancers had only small numbers
of CNAs. This was not associated with a lower tumor percentage in
these samples. Examination of the array CGH data of LaPointe et al.
[7] reveals a similar phenomenon. Thus, there seems to be a subset of
prostate cancers with low levels of genomic instability.
We went on to define the top CNA regions by average copy num-
ber change in our tumor cohort (Figure 2). For each SNP, the average
fold difference between tumor and normal samples was computed
across the 20 tumors; to assess regions of high or recurrent gain,
the overrepresentation of SNPs having high averages (>0.2) was de-
termined for each cytoband region (A); similarly, the overrepresenta-
tion of SNPs having low averages in each cytoband (<−0.2) was used
to assess recurrent loss (Figure 2B). Overrepresentation was statisti-
cally assessed for each cytoband to determine the top CNA regions
(Figure 2C ), and these cytoband regions were viewed as heat maps
(Figure 2D). By this approach, regions with recurrent but moderate
gain or loss in multiple tumors and regions with gain in only a single
tumor but with very high copy number (most notably 1q31.3-1q32.1;
Figure 2D, left panel) could be identified, both patterns of which are
relevant in cancer [19]. The regions of loss and gain identified are
broadly similar to those reported previously for CGH studies of clini-
cally localized prostate cancer [4]. Comparison of our results to the
consensus CGH data reported by Sun et al. [4] is shown in Table 2,
in which we compare our regions with significant loss and gain to the
consensus regions of loss or gain seen in at least 10% prostate cancers
identified in the meta-analysis by this group. In agreement with the
consensus CGH data, we observed loss of 2q21, 6q13-22, 8p12-23,
10q23, 13q13-31, 16q12-24, and 18q23 as well as gain of 7q31-34
and 8q11-24. Overall, we found loss or gain at 9 of the 13 consensus
regions identified by Sun et al. [4]. These findings argue strongly for
the technical validity of our analysis.
In addition, we identified loss at an additional 10 loci not among
the consensus sites identified by Sun et al. [4]. Interestingly, five of
these loci (1p36, 9q34, 10q26, 17q21, and 19p13) have been identi-
fied previously as sites of potential familial prostate cancer suscepti-
bility and/or aggressiveness genes [20–24]. Three of these have also
been identified as areas of loss in at least 20% advanced prostate cancer
tissues in individual studies [4,6,8,25]. Other loci that we have iden-
tified as lost (10p15, 17p13, 21q22, and 22q13) have also been iden-
tified as lost in at least 20% of advanced prostate cancer in individual
studies [4,7,8,11,25] but were not among the consensus regions iden-
tified by Sun et al. [4]. In particular, we noted loss at 17p13, the site of
the p53 locus and 21q22, the site of the TMPRSS2/ERG fusion gene
that has recently been shown to occur in approximately 50% of hu-
man prostate cancers. Finally, we noted gain of 1q31 and 7p13-22,
two regions that have been shown to be gained in advanced prostate
cancer [4,5,7]. The only unique CNA identified in our analysis that
has not been previously linked to prostate cancer is loss at 4p16.3.
We wished to compare the CNA patterns as observed in our data
set with those of previously published genomic profiling studies. Re-
cently, Lapointe et al. [7] profiled 55 primary tumors and 9 unmatched
therapy-naive pelvic lymph node metastases, using CGH on cDNA
Figure 1. Genome-wide CNAs in prostate cancer specimens from
AA patients. (A) Heat map representation of the 20 cancer speci-
mens (columns) across the 818 cytobands represented in the pro-
filing, ordered by genome position (rows). Mean log2 ratios for
cytobands comparing cancer to paired normal sample are depicted
by color gram (yellow indicates gain; blue, loss). Shaded boxes
above the heat map indicate grade and stage of tumor samples.
Gleason grade: light gray indicates 5-6; dark gray, 7; black, 8-9.
Pathological stage: white indicates T2b; light gray, T2c; dark gray,
T3a; black, T3b. Selected genes in recurrent regions of gain or loss
are indicated. (B) Fraction of genome (cytobands) harboring CNA for
tumor with low Gleason grade (5-6) versus high Gleason grade (7-9).
Box-and-whisker plots indicate median, lower and upper quartiles,
and the smallest and largest values. P value by two-sided t-test.
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microarrays representing ∼40K cDNA. Of the primary tumors in this
series, 45were fromwhites and 2were fromAA; for the remaining 8, the
race was not known (Jonathan Pollack and James Brooks, personal com-
munication). We compared the pathological data of the primary tumors
from white patients in this study with our tumors, and there was very
close concordance in Gleason scores and pathological stage (Table 1).
For each of the 767 cytoband regions represented in both our data set
and the Lapointe data set (hereafter referred to as Stanford), we repre-
sented the number of tumors in our cohort with copy number gain or
loss, using a frequency plot (Figure 3A). Similarly, we generated a fre-
quency plot for the primary tumors from white patients in the Stanford
data set for comparison (Figure 3B).
Many of the frequent aberrations previously reported in the study
of Lapointe et al. [7] were also frequent in ours, including gains at
8q (35% of our cases at 8q21) and losses at 13q (40% at 13q14), 8p
(40%), and 6q (45% at 6q21). Of note, 4p16.3 loss was not seen in
Figure 2. Top genomic regions of gain or loss by average copy number change in prostate tumors from the AA cohort. (A) For each of
the 818 cytobands represented, the number of SNPs with high averages (>0.2) across the 20 tumors, as a ratio of the number of chance
expected. High found/expected ratios may indicate significant regions of copy gain. (B) Number of SNPs with low averages (<−0.2), as a
ratio of the number of chance expected. High found/expected ratios here may indicate regions of loss. (C) Top cytoband regions of CNA
(yellow indicates gain; blue, loss), as assessed by χ2 statistic (which was a function of both the found/expected ratios of parts A and B,
as well as the absolute number of SNPs represented in each cytoband). (D) Heat map representation of regions of gain (left panel) or loss
(right panel) from part C, across the 20 tumors (same patient ordering as for Figure 1A).
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the Stanford cohort. We went on to compare the relative frequencies
of gain or loss between our primary tumors cohort and the white
patients in Stanford cohort (Figure 3C ). We found 17 cytobands
with a statistically higher frequency of gain (P < .01, one-sided Fisher
exact test) in our cohort over the Stanford cohort; although some of
these cytobands may have appeared nominally significant due to
multiple testing of 767 cytobands (chance expected = 8), we did see
a number of these enriched cytobands in regions of potential interest,
including 8q24 and 7p21. Conversely, we found 33 cytobands of loss
that were enriched in our cohort (P < .01), which well-exceeded chance
expected (∼8) and which included regions spanning 6q13-6q22.3,
8p23-8p12, 13q13-13q31, and 16q12-16q24. We also analyzed gains
or losses that were more frequent in the Stanford cohort compared
with our cohort, but we did not find many more than expected by
chance (gains, 3; losses, 9; and chance expected, 8).
We also determined the frequency of CNAs for the nine prostate
cancer metastases profiled in the Lapointe study (Figure 3D). Eight
of the nine metastatic tumors were from white patients, and in one
case, the race was unknown. Comparison of this plot with the plots
from our primary tumors and the primary tumors from white patients
analyzed by the Stanford group revealed a number of regions where our
primary tumors more closely resembled the metastatic lesions from the
Stanford study. These included a higher frequency of loss of 6q13-22,
8p21, 10p15, 13q13-14, and 16q11-24 and gains of 7p21 and 8q24.
To further explore the patterns of gains and losses in the two cohorts
we carried out hierarchical clustering (complete linkage method) of copy
gain/loss profiles of prostate tumors from Baylor cohort (N = 20) and
the entire Stanford cohort including metastatic lesions (N = 64). Inter-
estingly, 17 of the 20 Baylor cases (and 1 of 2 Stanford AA cases) were
in two major clusters (Figure 4, left side). A subtree of the dendrogram
(highlighted in red) contained 7 of the 10 Baylor cases, 6 of which were
T3 cancers, and 5 of 9 metastatic tumors. Both the Stanford metastasis
samples and the Baylor T3 samples were overrepresented (P = .02 and
P = .01, respectively, one-sided Fisher exact test). Thus, this subtree con-
sisted of aggressive cancers and is characterized by loss of 8p, 13q, and
16q and gain of 8q. Of note, the white T3 cancers were not enriched in
this subtree. A second major subtree contained 10 of the Baylor cases,
including 7 of 9 T2 cancers. Thus, this subtree was enriched with the
less aggressive AA cancers. Notable features of cancers in this subtree
were loss of 6q and infrequent loss 13q. Therefore, it seems that prostate
cancers in AA men can be divided into more aggressive and less aggres-
sive subgroups based on the pattern on CNAs.
Discussion
To date, most studies of genomic CNAs in prostate cancer have
analyzed prostate cancer tissues from white patients. Thus, there is
only limited data regarding CNAs in prostate cancer in AA men.
Our studies indicate that the regions of loss and gain are similar in
AA men and white men. Most of the loci that we have identified as
being lost or gained in prostate cancers from AA men have previously
been identified as being altered in prostate cancer in studies consist-
ing predominantly or exclusively of white patients. Several of the loci
have also been linked to familial prostate cancer susceptibility. Thus,
the regions of loss and gain in prostate cancer in AA and white men
appear to be broadly similar. The only unique CNA identified in our
analysis that has not been previously linked to prostate cancer is loss
of 4p16.3. Loss of this region has been previously noted in breast,
bladder, and colon cancers [30–32]. The region of loss contains 46
identified genes, several of which are candidate tumor suppressor
genes. MXD4 (also known as hMAD4) is a MAX-binding protein
and a transcriptional repressor that can block myc-dependent cell
transformation and may play a role in cellular senescence [33]. CRIPak
[34] encodes a protein that is a negative regulator Pak1 (p21-activated
kinase). Pak1 promotes cellular motility and has been shown to have
antiapoptotic activities in prostate cancer cells [35], so loss of its inhibi-
tor would potentially be tumor-promoting. Larger studies will be
Table 2. Comparison of Copy Number Alterations in AA Men with Previously Reported Genomic Loci Implicated in Prostate Cancer.






8p12-23 8p21-23 [4,5] NKX3.1 locus
9q34 [21]
10p15 [25] Implicated by functional studies [27]
10q23 10q23-25 [4,5,7,25] PTEN locus
10q26 [4,25] [22]
13q13-31 13q14-22 [4,5,26] RB1 and BRCA2 loci
16q12-24 16q13-24 [4] [22]
17p13 [7,8] p53 locus
17q21 [8] [23]
18q23 18q12-23 [4]
19p13 [6] [24] Implicated by functional studies [28]






8q11-24 8q21-24 [4,5,7] [29]
17q24-25
Xq11-21 [4]
*Consensus CGH is based on the meta-analysis of Sun et al. [4] of CGH studies summarizing regions with changes in at least 10% of all tumors analyzed.
†Loci were considered to be altered in advanced prostate cancer if alterations were identified in at least 20% of advanced cancers in the individual study referenced. The 20% threshold was chosen owing
to the higher background rate of genomic alterations in such cancers.
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needed to validate whether this loss occurs in other prostate cancers
from AA and/or white men.
Although our studies indicate that the loci of loss and gain are
broadly similar between AA and white patients, there are indications
of significant quantitative differences. When we compared our clini-
cally localized cancers from our AA cohort to the white patients from
the cohort examined by Lapointe et al. [7], we found multiple regions
that had significantly higher rates of loss (1p36, 2q21, 4p16, 6q13-22,
8p21, 9q34, 10p15, 11p15, 13q13-14, 16q11-24, 17p13, 17q21,
21q22, and 22q13) and gain (3p21, 7p21, 8q24, 20p11, and
20q11). Examination of the losses and gains detected by LaPointe
et al. [7] indicates that there are multiple regions where the CNAs
in AA prostate cancer are more similar to metastatic disease than the
clinically localized disease cohort. Particularly striking are gains of
chromosome 7 and 8q and loss of 16q. The gain of 8q, particularly
the 8q24 region, has been repeatedly linked to aggressive disease in
prostate cancer [5,7], and there is a risk allele for prostate cancer in
AA men in this region [29]. However, other regions that are altered
in the metastatic tumors analyzed by LaPointe et al. [7] are not altered
in the clinically localized prostate cancers in AA men, such as losses on
chromosome 4 and 12p and gains on broad regions of 9q. Thus, the
increased CNAs in prostate cancers from AA men are specific and do
not reflect nonspecific chromosomal loss or gain. Cluster analysis of
the two cohorts confirms this analysis and reveals that T3 lesions in
AA men seems more closely related to the Stanford metastases than
to the Stanford T3 samples.
In addition to the more frequent gains and losses we noted in pri-
mary cancers from AA men when compared with the primary cancers
in the Stanford cohort, we also noted that we did not see significant
loss on 5q. LaPointe et al. [7] have correlated CNA and expression
profiles in their cohort. This group had previously identified three sub-
types of prostate cancer based on expression profiling [36]. Subtype 1
was associated with better prognosis, and one of the defining CNAs
associated with this subtype is loss of 5q [7]. Our finding suggests that
subtype 1 prostate cancers may be less common in AA men. Given
that the grade and stage of our cohort and that of Lapointe et al.
[7] were very similar, this finding cannot be explained by differences
in standard pathological markers of disease aggressiveness between the
two groups. All of our findings suggest that at a similar stage, prostate
cancers in AA men may harbor patterns of CNAs that are associated
with more aggressive disease.
Finally, it is of interest to note that the AA patients have more frequent
loss at 21q22.3 than the white patients. This locus corresponds to the
recently described TMPRSS2/ERG fusion gene that is found in the 40%
to 80% of prostate cancers analyzed to date [37–39]. This fusion results
in juxtaposition of the androgen-regulated TMPRSS2 promoter and the
ERG oncogene. The ERG oncogene is expressed at variable levels in
prostate cancers with the gene fusion [39] and has pleiotropic tumor-
promoting activities [40]. As summarized by Freedland and Isaacs [1],
AA men have been shown to have variations in various components
of the androgen signaling pathway including higher serum androgen lev-
els, 5-alpha reductase isoenzyme activity, testosterone biosynthesis or
Figure 3. Tumors from AA patients in the Baylor cohort exhibit both similar and distinct patterns of CNA, compared with tumors from an
independent cohort of predominantly white patients. (A) Frequency plot summarizing the distribution of CNAs in the Baylor cohort.
Yellow indicates gain; blue, loss. Number (n) of specimens represented is indicated. (B) Frequency plot summarizing the distribution
of CNAs in white patients from an independent cohort of patients (primaries only), from a previously published CGH array data set by
Lapointe et al. [7] (“Stanford” cohort). (C) Regions of copy gain (yellow) and loss (blue) nominally overrepresented in the Baylor cohort
compared with the white patients from the Stanford cohort (P < .01, one-sided Fisher exact test). (D) Frequency plot summarizing the
distribution of CNAs in lymph node metastases from the Lapointe study.
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degradation pathways, androgen receptor levels, and trinucleotide repeats
affecting androgen receptor signaling. The net effect of all these altera-
tions would be higher androgen receptor activity in AA men [1]. Thus,
it is possible that AA men express higher levels of the TMPRSS2/ERG
fusion gene transcript when the fusion gene is present and thus are more
likely to develop clinically significant cancers bearing this gene fusion.
Further work is needed to explore this hypothesis.
Our results are consistent with the results of Cher et al. [12], in
that almost all the regions of CNA in prostate cancers from AA men
were also lost in white men. We also observed increased loss at the
p53 locus at 17p13 in our AA cohort compared with the white pa-
tients from the Stanford cohort, consistent with the prior observation
of Cher et al. [12]. However, we did find an increased frequency of
CNAs in multiple regions in prostate cancer tissues from AA men, in
contrast to the results of Cher et al. [12]. One potential confounding
variable in the studies of Cher et al. [12] was that 4 of their 16 cases
from whites were poorly differentiated (Gleason 8-9) versus only 1 of
16 cases from AA men. Given that poorly differentiated cancers tend
to have more CNAs than better differentiated lesions (Figure 1 and
references [10] and [11]), this could have masked differences in CNA
frequency between the two groups. Clearly, more extensive studies
are needed to resolve this question.
In summary, our study has found that although CNAs in prostate
cancers from AA men are broadly similar to those found white men,
there are significant differences in the frequency of particular CNAs.
Prostate cancers from AA men tended to have lower rates of loss of
5q, loss of which is associated with less aggressive disease, and more
frequent losses and gains of several regions associated with metastatic
disease such as gain of 8q24. It should be noted that although these
observations are important, there are limitations to our study includ-
ing the relatively small size of our AA cohort and lack of exact clinical
and pathological matching to the Stanford cohort. Another variable is
that the analytical platforms differed in the two groups. However,
given the extremely high concordance of our CNA results with previ-
ously reported studies in white men, it seems unlikely that this impacts
our overall result. It is possible that our more dense arrays may detect
losses in very small regions not represented in less dense arrays; at the
same time, however, it seems unlikely that the differences noted in
broad regions such as chromosome 6q13-22, 8p21, 8q24, 13q13.1-
14.3, and 16q11-24.3 would be impacted by the analytical platform.
Furthermore, the differences between our cohort and the Stanford
cohort were confined to specific regions, not all regions of CNA, again
arguing for the analytical platform not representing a major determi-
nant in the differences we observed. In the future, it will be critical to
Figure 4. Hierarchical clustering (complete linkage method) of copy gain/loss profiles of prostate tumors from Baylor (N = 20) and
Stanford cohorts (N = 64). Gain or loss events (from Figure 3) are depicted by heat map color gram (yellow indicates gain). Shaded
boxes above the heat map indicate cohort (Baylor or Stanford), race, primary versusmetastasis, and stage. A subtree of the dendrogram
is highlighted in red, for which both the Stanford metastasis samples and the Baylor T3 samples are overrepresented (P = .02 and P =
.01, respectively, one-sided Fisher exact test).
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replicate these studies in larger groups of AA and white men who are
carefully matched using existing clinical and pathological variables and
profiled by the same analytical platform. Such studies may give criti-
cal new insights into the biological basis of aggressive prostate cancer
in AA men.
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